Compare Abeona Therapeutics Inc (ABEO) vs T Rowe Price Group Inc (TROW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs T Rowe Price Group Inc — how do they compare? Abeona Therapeutics Inc trades at $6.71 (market cap $373.32M), while T Rowe Price Group Inc trades at $117 (market cap $25.75B). The key difference: T Rowe Price Group Inc is far larger — about 69× Abeona Therapeutics Inc's market cap, and T Rowe Price Group Inc pays a 4.33% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | TROW | |
|---|---|---|
Market Cap | $373.32M | $25.75B |
Sector | Health | Financials |
52-Week High | $7.23 | $120.16 |
52-Week Low | $4.17 | $86.19 |
Enterprise Value | $228.22M | $22.45B |
Dividend Yield | — | 4.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
T. Rowe Price (TROW) trades at $120.16, up 1.36% with bullish technical indicators showing strong momentum above key support levels. The company maintains solid fundamentals with $7.31B revenue, 28.28% net margin, and attractive valuation at 12.78 P/E. Recent earnings beat expectations in Q1 2026, while strategic initiatives in institutional services and AI-focused content demonstrate proactive positioning.
TROW presents a mixed outlook with strong profitability and cash flow generation offset by analyst caution. The stock trades above consensus target ($101.57) but offers dividend appeal with recent $1.30 payout. Key risks include equity outflows and market sensitivity, while institutional enhancements and debt-free balance sheet provide stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About T Rowe Price Group Inc
T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load U.S. and international stock, hybrid, bond, and money market funds. At the end of August 2022, the firm had $1.339 trillion in managed assets, composed of equity (54%), balanced (30%), fixed-income (13%), and alternatives (3%) offerings. Approximately two thirds of the company's managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a U.S.-based asset manager, deriving just under 10% of its AUM from overseas.
Read more on TROW →
